Back to rankings

Balchem Corporation (BCPC)

NEUTRAL
Basic MaterialsSpecialty ChemicalsUnited States

Fundamental

71

Price

$177.16

Market Cap

$5.79B

Part 1 · What the company is worth

Overview

Balchem Corporation develops, manufactures, and distributes specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products. The Human Nutrition & Health segment supplies ingredients in the food and beverage industry. Its products include spray dried and emulsified powders, extrusion and agglomeration, blended lipid systems, liquid flavor delivery systems, juice and dairy bases, chocolate systems, and cereal systems, as well as ice cream bases and variegates. This segment offers specialty vitamin K2; microencapsulation solutions for various applications; and human grade choline nutrients and mineral amino acid chelated products for nutrition and health applications. The Animal Nutrition & Health segment provides microencapsulated products to enhance health and milk production and delivering nutrient supplements in ruminant animals; chelation technology, which offers enhanced nutrient absorption for various species of production and companion animals; methylsulfonylmethane; and choline chloride, a nutrient for monogastric animal health. The Specialty Products segment distributes ethylene oxide and ammonia primarily for use in the health care industry; and single use canisters for sterilizing re-usable devices. This segment also markets and sells propylene oxide, a fumigant to aid in the control of insects and microbiological spoilage, as well as to reduce bacterial and mold contamination in shell and processed nut meats, processed spices, cacao beans, cocoa powder, raisins, figs, and prunes; and chelated minerals for high value crops. It sells its products through sales force, independent distributors, and sales agents. The company was incorporated in 1967 and is headquartered in Montvale, New Jersey.

No editorial profile for this company yet

Direct competitors

Who this company fights with for the same customers

No editorial profile for this company yet

No competitor list for this company yet.

Balance Sheet & Liquidity

Revenue

$1.09B

Trailing 12 months (through 6/30/2026)

Net Income

$164M

Trailing 12 months (through 6/30/2026)

Free Cash Flow

-

Total Equity

$1.26B

Total Liabilities

$429M

Current Ratio

2.66

Interest Coverage

-

Debt/EBITDA

0.65

Earnings Per Share

Revenue & Net Income

Free Cash Flow

Income Breakdown

Historical statement

Margins over time

Debt over time

How heavy the debt is

Growth grid

Growth — Revenue

Fair Value Estimation

CyclicalOvervalued

Fair Value

$126.59

Current Price

$177.16

Margin of Safety

-40.0%

Fair Value Range

$82.29 - $170.90

Estimation Methods

Analyst price target:$209.25
Discounted cash flow (DCF):Not applicable to this type of company
Earnings multiple (P/E):$139.20
Graham growth formula:Not applicable to this type of company
Earnings power value (EPV):$58.90
Justified P/B:Not applicable to this type of company
Dividend discount (Gordon):Not applicable to this type of company
P/FFO, funds from operations:Not applicable to this type of company
Mid-cycle earnings:$95.30
Revenue multiple:Not applicable to this type of company
Analyst Consensus:Strong Buy (7B / 2H / 0S)
Last Earnings Surprise:+4.72%

Valuation Metrics

P/E Ratio

34.87

ROE

12.3%

P/B Ratio

4.34

P/FCF

-

Gross Margin

36.3%

ROIC

10.9%

Profitability Radar

Value Creation (Economic Moat)

ROIC

10.9%

WACC

9.0%

ROIC − WACC

+2.0 pp

ROIC exceeds the cost of capital — the company is creating value for shareholders.

Fundamental Analysis Criteria

Passed (17)

  • EPS shows upward trend
  • EPS CAGR 10.73%
  • Price CAGR 8.01%
  • ROIC 11.0%
  • Gross Margin 36.3%
  • Debt/Equity ratio
  • Operating Margin 20.2%
  • Current Ratio
  • Debt/EBITDA
  • Return on Tangible Assets
  • ROE 12.8%
  • Revenue Growth 5Y 8.1%
  • Analyst Consensus 78% Buy
  • Earnings Quality (OCF/NI) 1.34
  • Share Dilution -0.3%
  • Net Margin Trend 15.1% vs 14.5%
  • Piotroski F-Score 9/9

Failed (6)

  • P/B Ratio 4.34
  • Low reliance on intangibles
  • Price below Graham Number
  • DCF valuation (Overvalued)
  • Earnings Surprise avg 0.9%
  • PEG Ratio 2.72

Unavailable (5)

  • P/FCF NaN
  • Dividend Payout NaN%
  • Positive Free Cash Flow
  • CapEx intensity
  • Interest Coverage

Piotroski F-Score

9/9

Strong financial health

score
criteria

Earnings Quality

1.34

High quality: earnings backed by cash

Share Dilution

-0.3%

Buying back shares. Shareholder friendly

Governance

Executive Team

NameTitleAge
Mr. Theodore Lee HarrisCEO, President & Chairman60
Mr. Carl Martin BengtssonExecutive VP, CFO, Treasurer and GM of Animal Nutrition & Health48
Ms. Hatsuki Miyata J.D.Executive VP, Chief Legal Officer & Secretary49
Mr. M. Brent TignorSenior VP & Chief Human Resources Officer47
Mr. Frederic BonedSenior VP, Head of Digital Transformation & AI and GM of Human Nutrition & Health46
Ms. Erin L. GilsonVP & Chief Accounting Officer-
Mr. Martin Luther ReidSenior VP & Chief Supply Chain Officer58
Mr. Job L. van GunsterenSenior VP & GM of Specialty Products48
Mr. George GrahamSenior VP and Chief R&D Officer55

Audit Risk

3

Board Risk

4

Compensation Risk

4

Shareholder Rights Risk

7

Part 2 · The price and when to enter

This part won't tell you whether the company is worth owning: it helps you choose when to buy it, once the fundamentals have convinced you. Inside: technical analysis, potential, historical drawdowns, gamma exposure.

Latest News

Recent headlines for BCPC, sourced from Markets Gazette.

No recent news for BCPC.